Literature DB >> 3486067

Extractable nuclear antigen (ENA) autoantibodies in SLE: an immunogenetic relationship with HLA, C4 and Bf alleles.

R S Warlow, G Uko, J McCluskey, P H Kay, F T Christiansen, R L Dawkins.   

Abstract

Sera from 36 subjects with systemic lupus erythematosus (SLE) were examined for extractable nuclear antigen (ENA) autoantibodies by immunoassay with the ribonucleoprotein (RNP) subset being determined by immunodiffusion. The prevalence of the genetic markers of HLA, the fourth complement component (C4) and properdin factor (Bf), which are all coded for within the major histocompatibility complex on chromosome 6 were analysed in relation to various parameters of these autoantibodies. The following associations were observed: The lowest ENA antibody titres of the RNP negative group were associated with HLA A9 (P less than 0.05), while the lowest RNA-ase sensitive ENA (RSE) subset antibody levels were associated with HLA Dr 1 (P less than 0.05). For the complement markers, C4 AQo was associated with the lowest affinity ENA antibodies (P less than 0.05), while the BF F allele and Fs phenotype had lower RSE antibody levels than did the S allele (P less than 0.05) and the SS phenotype (P less than 0.05) respectively. This study demonstrated diverse association between various MHC markers and ENA antibody parameters, indicating that there are distinctive immunogenetic influences over ENA autoantibodies in SLE.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486067      PMCID: PMC1577383     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  A rapid screening enzyme linked immunosorbent assay for autoantibodies to extractable nuclear antigens.

Authors:  R Warlow; J Carrano; R Dawkins
Journal:  Diagn Immunol       Date:  1984

Review 2.  Current perspectives on serological reactions in SLE patients.

Authors:  M Reichlin
Journal:  Clin Exp Immunol       Date:  1981-04       Impact factor: 4.330

3.  Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus.

Authors:  E M Tan; H G Kunkel
Journal:  J Immunol       Date:  1966-03       Impact factor: 5.422

4.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

5.  Serological findings in patients with "ANA-negative" systemic lupus erythematosus.

Authors:  P J Maddison; T T Provost; M Reichlin
Journal:  Medicine (Baltimore)       Date:  1981-03       Impact factor: 1.889

6.  HLA antigens and Bf allotypes in SLE: evidence for the association being with specific haplotypes.

Authors:  C M Black; K I Welsh; A Fielder; G R Hughes; J R Batchelor
Journal:  Tissue Antigens       Date:  1982-02

7.  Complement allotyping in SLE: association with C4A null.

Authors:  F T Christiansen; R L Dawkins; G Uko; J McCluskey; P H Kay; P J Zilko
Journal:  Aust N Z J Med       Date:  1983-10

8.  Antibodies to nuclear antigens in polymyositis: relationship to autoimmune 'overlap syndromes' and carcinoma.

Authors:  P J Venables; P A Mumford; R N Maini
Journal:  Ann Rheum Dis       Date:  1981-06       Impact factor: 19.103

9.  Inherited structural polymorphism of the fourth component of human complement.

Authors:  Z L Awdeh; C A Alper
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

10.  Associations of antibodies to native DNA with HLA-DRw3. A possible major histocompatibility complex-linked human immune response gene.

Authors:  W L Griffing; S B Moore; H S Luthra; C H McKenna; C G Fathman
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  1 in total

1.  HLA-DR4 and Gm(1,3;5,21) are associated with U1-nRNP antibody positive connective tissue disease.

Authors:  E Genth; H Zarnowski; R Mierau; D Wohltmann; P W Hartl
Journal:  Ann Rheum Dis       Date:  1987-03       Impact factor: 19.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.